Haddad, D.; Dsouza, V.S.; Al-Mulla, F.; Al Madhoun, A. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int. J. Mol. Sci.2024, 25, 571.
Haddad, D.; Dsouza, V.S.; Al-Mulla, F.; Al Madhoun, A. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int. J. Mol. Sci. 2024, 25, 571.
Haddad, D.; Dsouza, V.S.; Al-Mulla, F.; Al Madhoun, A. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int. J. Mol. Sci.2024, 25, 571.
Haddad, D.; Dsouza, V.S.; Al-Mulla, F.; Al Madhoun, A. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment. Int. J. Mol. Sci. 2024, 25, 571.
Abstract
Achieving glycemic control and sustaining functional pancreatic β-cell activity remains an unmet medical need in the treatment of type 2 diabetes mellitus (T2DM). Glucokinase activators (GKAs) constitute a class of anti-diabetic drugs designed to regulate blood sugar levels and enhance β-cell function in patients with diabetes. A significant progression in GKA development is underway to address the limitations of earlier generations. Dorzagliatin, a dual-acting GKA, targets both the liver and pancreas and has successfully completed two Phase III trials, demonstrating favorable results in diabetes treatment. The hepato-selective GKA—TTP399— emerges as a strong contender, displaying clinically noteworthy outcomes with minimal adverse effects. This paper seeks to review the current literature, delve into the mechanisms of action of these new-generation GKAs, and assess their efficacy and safety in treating T2DM based on published pre-clinical studies and clinical trials.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
